Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection. There is also an albumin-bound formulation.
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA, based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East. It was closed in 2019 after its acquisition by Bristol Myers Squibb.
Leo Sachs was a German-born Israeli molecular biologist and cancer researcher. Born in Leipzig, he emigrated to the United Kingdom in 1933, and to Israel in 1952. There he joined the Weizmann Institute of Science.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.
Carmustine, sold under the brand name BiCNU among others, is a medication used mainly for chemotherapy. It is a nitrogen mustard β-chloro-nitrosourea compound used as an alkylating agent.
The Robert Wood Johnson University Hospital (RWJUH) is a 965-bed hospital with campuses in New Brunswick, and Somerville, New Jersey, and serves as a flagship hospital of RWJBarnabas Health.
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
The Bristol-Myers Squibb Children's Hospital at Robert Wood Johnson University Hospital (BMSCH) is a freestanding, 105-bed pediatric acute care children's hospital adjacent to RWJUH. It is affiliated with both Robert Wood Johnson Medical School and the neighboring PSE&G Children's Specialized Hospital, and is one of three children's hospitals in the RWJBarnabas Health network. The hospital provides comprehensive pediatric specialties and subspecialties to infants, children, teens, and young adults aged 0–21 throughout New Jersey and features an ACS verified level II pediatric trauma center. Its regional pediatric intensive-care unit and neonatal intensive care units serve the Central New Jersey region.
Robert Joseph Lefkowitz is an American physician and biochemist. He is best known for his groundbreaking discoveries that reveal the inner workings of an important family G protein-coupled receptors, for which he was awarded the 2012 Nobel Prize for Chemistry with Brian Kobilka. He is currently an Investigator with the Howard Hughes Medical Institute as well as a James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry at Duke University.
Samuel J. Danishefsky is an American chemist working as a professor at both Columbia University and the Memorial Sloan-Kettering Cancer Center in New York City.
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie.
Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.
Jeremy Levin is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is administered intravenously.
Werner Henle and Gertrude Henle were a husband and wife team of German-American virologists. The National Library of Medicine called them "a prodigious force in virology, immunology and viral oncology during the second half of the 20th century".
Charles J. Sherr is the chair of the Tumor Cell Biology Department at St. Jude Children's Research Hospital. He studies tumor suppressor genes and cell division.
Sir Joel Ivor Mann, generally known as Jim Mann, is a New Zealand nutritionist and endocrinologist. He is professor in human nutrition and medicine at the University of Otago and consultant physician (endocrinology) at Dunedin Hospital. He has researched the role of lipids and carbohydrates in coronary heart disease, diabetes, and obesity, as well as the relationship between obesity and cancer. He was knighted in the 2022 New Year Honours.
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion.
